Digital Health Is Fastest Growing Segment Fueling The Growth Of Cardiac Autonomic Control Market

 

Cardiac Autonomic Control Market

The global Cardiac Autonomic Control Market is estimated to be valued at US$ 16.84 Bn in 2023 and is expected to exhibit a CAGR of 7.4% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Overview:

Cardiac autonomic control market refers to devices that control and monitor the autonomic functions such as heart rate variability, heart rate, ECG signal, respiration and other functions when the brain signals become abnormal. Cardiac autonomic control devices are significantly important for patients suffering from cardiac disorders by monitoring and controlling the autonomic functions of the heart.

Market key trends:

The use of remote monitoring and digital health solutions is increasing rapidly in the cardiac autonomic control market. Technological advancements have enabled collecting important patient data remotely and maintaining regular check on the condition without visiting hospitals frequently. This allows early detection of abnormalities and taking preventive actions. Remote monitoring solutions offer convenience to patients and reduce burden on healthcare systems.

Segment Analysis

The global cardiac autonomic control market is segmented based on product type and end user. Based on product type, the market is classified into implantable cardioverter defibrillators, cardiac resynchronization therapy devices, and pacemakers. The pacemakers segment dominate the market and accounts for the largest revenue share due to the increasing prevalence of atrial fibrillation and congestive heart failures. The end user segment of the market includes hospitals, ambulatory surgical centers, and cardiac centers. The hospitals segment generates highest revenue in the market owing to availability of advanced healthcare facilities and skilled professionals.

Key Takeaways

The Global Cardiac Autonomic Control Market Demand is expected to witness high growth, exhibiting CAGR of 7.4% over the forecast period, due to increasing prevalence of cardiovascular diseases. The market size is projected to reach US$ 16.84 Bn by 2023.

Regional analysis: North America dominates the global market and is expected to maintain its dominance over the forecast period. This is attributed to the growing geriatric population, availability of advanced cardiac devices and high healthcare expenditure in the region. Asia Pacific exhibits the highest growth rate owing to rising healthcare awareness, growing medical tourism industry and increasing discretionary funding for development of healthcare infrastructure in emerging countries.

Key players analysis: Key players operating in the cardiac autonomic control market are Medtronic plc, Abbott Laboratories, Boston Scientific Corporation, Biotronik SE & Co. KG, MicroPort Scientific Corporation, LivaNova PLC, Nihon Kohden Corporation, Schiller AG, Johnson & Johnson, GE Healthcare. Medtronic plc holds the largest market share owing to its robust product portfolio and widespread geographical presence across the globe.

Read More;

https://www.marketwebjournal.com/cardiac-autonomic-control-market-demand-growth-and-forecast/